Chronic pain is among the most prevalent
burdensome disorders worldwide.
The N-methyl-d-aspartate (NMDA) receptor
system plays a critical role in central sensitization, a primary feature
of chronic pain. Despite the proven efficacy of exogenous ligands
to this receptor system in preclinical studies, evidence for the clinical
efficacy of NMDA antagonists for the treatment of chronic pain is
weak. Researchers are studying alternate approaches, rather than direct
inhibition of the NMDA receptors in pain processing neurons. This
indirect approach utilizes the modulation of molecular switches that
regulates the synthesis, maturation, and transport of receptors from
cellular organelles to the synaptic membrane. Kinesins are nanomotors
that anterogradely transport the cargo using microtubule tracks across
the neurons. Various members of the kinesin family, including KIF17,
KIF11, KIF5b, and KIF21a, regulate the intracellular transport of
NMDA receptors. Pharmacological targeting of these ATP-driven nanomotors
could be a useful tool for manipulating the NMDAR functioning. It
could provide the potential for the development of a novel strategy
for the management of chronic pain.